Resistance Mechanisms to Anti-PD Cancer Immunotherapy DOI
Matthew D. Vesely,

Tianxiang Zhang,

Lieping Chen

и другие.

Annual Review of Immunology, Год журнала: 2022, Номер 40(1), С. 45 - 74

Опубликована: Апрель 26, 2022

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1 (B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However, only a fraction patients with solid tumors and some hematopoietic malignancies respond to anti-PD therapy, reason for failure in other is less known. By dissecting mechanisms underlying this resistance, current studies reveal that tumor microenvironment major location resistance occur. Furthermore, appear be highly heterogeneous. Here, we discuss recent human data identifying therapy. We review evidence immune-based such as loss neoantigens, defects antigen presentation interferon signaling, immune inhibitory molecules, exclusion T cells. also clinical emerging alterations metabolism, microbiota, epigenetics. Finally, strategies overcome therapy emphasize need develop additional immunotherapies based on concept normalization immunotherapy.

Язык: Английский

Metabolic reprogramming and cancer progression DOI
Brandon Faubert, Ashley Solmonson, Ralph J. DeBerardinis

и другие.

Science, Год журнала: 2020, Номер 368(6487)

Опубликована: Апрель 9, 2020

Metabolism as cancer progresses Numerous cancer-specific alterations in metabolism have been identified but not yet resulted an effective anti therapeutic. In a Review, Faubert et al. discuss how changes develops from small, premalignant lesion to aggressive primary tumor and then metastasizes. Metabolic vulnerabilities likely change with progression, making the identification of general cancer-associated metabolic features difficult. The authors propose that more targeted approach tissues patients may be effective. Science , this issue p. eaaw5473

Язык: Английский

Процитировано

1750

Cancer metabolism: looking forward DOI
Inmaculada Martínez‐Reyes, Navdeep S. Chandel

Nature reviews. Cancer, Год журнала: 2021, Номер 21(10), С. 669 - 680

Опубликована: Июль 16, 2021

Язык: Английский

Процитировано

1268

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade DOI Creative Commons
Golnaz Morad, Beth A. Helmink, Padmanee Sharma

и другие.

Cell, Год журнала: 2021, Номер 184(21), С. 5309 - 5337

Опубликована: Окт. 1, 2021

Язык: Английский

Процитировано

1102

The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities DOI
Won Jin Ho, Elizabeth M. Jaffee, Lei Zheng

и другие.

Nature Reviews Clinical Oncology, Год журнала: 2020, Номер 17(9), С. 527 - 540

Опубликована: Май 12, 2020

Язык: Английский

Процитировано

902

The cancer metabolic reprogramming and immune response DOI Creative Commons

Longzheng Xia,

Linda Oyang,

Jinguan Lin

и другие.

Molecular Cancer, Год журнала: 2021, Номер 20(1)

Опубликована: Фев. 5, 2021

The overlapping metabolic reprogramming of cancer and immune cells is a putative determinant the antitumor response in cancer. Increased evidence suggests that metabolism not only plays crucial role signaling for sustaining tumorigenesis survival, but also has wider implications regulation through both release metabolites affecting expression molecules, such as lactate, PGE2, arginine, etc. Actually, this energetic interplay between tumor leads to competition ecosystem, limiting nutrient availability leading microenvironmental acidosis, which hinders cell function. More interestingly, indispensable process maintaining self body homeostasis by various types cells. At present, more studies pointed out would undergo during proliferation, differentiation, execution effector functions, essential response. Herein, we discuss how regulate possible approaches targeting pathways context anticancer immunotherapy. We describe hypothetical combination treatments immunotherapy intervening could be used better unleash potential therapies.

Язык: Английский

Процитировано

773

Targeting cancer metabolism in the era of precision oncology DOI Open Access

Zachary E. Stine,

Zachary T. Schug, Joseph M. Salvino

и другие.

Nature Reviews Drug Discovery, Год журнала: 2021, Номер 21(2), С. 141 - 162

Опубликована: Дек. 3, 2021

Язык: Английский

Процитировано

773

Cell-programmed nutrient partitioning in the tumour microenvironment DOI
Bradley I. Reinfeld, Matthew Z. Madden, Melissa M. Wolf

и другие.

Nature, Год журнала: 2021, Номер 593(7858), С. 282 - 288

Опубликована: Апрель 7, 2021

Язык: Английский

Процитировано

750

Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy DOI Creative Commons
Jackie E. Bader, Kelsey Voss, Jeffrey C. Rathmell

и другие.

Molecular Cell, Год журнала: 2020, Номер 78(6), С. 1019 - 1033

Опубликована: Июнь 1, 2020

Язык: Английский

Процитировано

744

Glutamine reliance in cell metabolism DOI Creative Commons

Hee Chan Yoo,

Ya Chun Yu, Yulseung Sung

и другие.

Experimental & Molecular Medicine, Год журнала: 2020, Номер 52(9), С. 1496 - 1516

Опубликована: Сен. 1, 2020

Abstract As knowledge of cell metabolism has advanced, glutamine been considered an important amino acid that supplies carbon and nitrogen to fuel biosynthesis. A recent study provided a new perspective on mitochondrial metabolism, offering mechanistic insights into metabolic adaptation during tumor hypoxia, the emergence drug resistance, glutaminolysis-induced reprogramming presenting strategies target in cancer cells. In this review, we introduce various biosynthetic bioenergetic roles based compartmentalization explain why cells exhibit reliance glutamine. Additionally, examined whether derivatives contribute epigenetic regulation associated with tumorigenesis. addition, discussing transporters, propose for therapeutic intervention cancer.

Язык: Английский

Процитировано

681

Metabolism of immune cells in cancer DOI
Robert D. Leone, Jonathan D. Powell

Nature reviews. Cancer, Год журнала: 2020, Номер 20(9), С. 516 - 531

Опубликована: Июль 6, 2020

Язык: Английский

Процитировано

616